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ABSTRACT
3ULPDU\ELOLDU\FLUUKRVLV3%&LVDQLQÀDPPDWRU\GLVHDVHRUFKURQLFOLYHULQÀDPPDWLRQZLWKVORZSURJUHVVLYH
FKDUDFWHULVWLFDQGLVDQXQNQRZQFKROHVWDWLFOLYHUGLVHDVHDQGFRPPRQO\KDSSHQLQPLGGOHDJHGZRPHQ7KH
LQFLGHQFHRI3%&LV±SHUSHRSOHSHU\HDUSUHYDOHQFHRISHUSHRSOHDQG
FRQWLQXHVWRLQFUHDVH%DVHGRQWKH$PHULFDQ$VVRFLDWLRQIRU6WXG\RI/LYHU'LVHDVHFULWHULDWKHGLDJQRVLVRI
3%&LVPDGHLQWKHSUHVHQFHRIWZRRXWRIWKUHHFULWHULDZKLFKDUHLQFUHDVHRIDONDOLQHSKRVSKDWDVHSRVLWLYH
DQWLPLWRFKRQGULDODQWLERGLHV$0$DQGKLVWRSDWKRORJ\H[DPLQDWLRQ
:HUHSRUWHGDFDVHZKLFKLVYHU\UDUHO\IRXQGD\HDUROGZRPHQZLWKWKHFKLHIFRPSODLQWVRIGHFUHDVH
FRQVFLRXVQHVV DQG MDXQGLFH ,Q SK\VLFDO H[DPLQDWLRQ WKHUHZHUH DQDHPLF FRQMXQFWLYD LFWHULF VFOHUD
KHSDWRVSOHQRPHJDO\SDOPDUHU\WKHPDDQGOLYHUQDLOV,QWKHSDWLHQWWKHUHZDVQRHYLGHQFHRIREVWUXFWLRQLQ
LPDJLQJZLWKWZRIROGLQFUHDVHRIDONDOLQHSKRVSKDWDVHDQGSRVLWLYH$0$WHVW3DWLHQWZDVKRVSLWDOLVHGWRVORZ
GRZQWKHSURJUHVVLRQRIWKHGLVHDVHDQGWRRYHUFRPHWKHVLJQVHJSUXULWXVRVWHRSRURVLVDQGVLFFDV\QGURPH
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ABSTRAK
3ULPDU\ELOLDU\FLUUKRVLV3%&PHUXSDNDQSHQ\DNLWLQÀPDVLDWDXSHUDGDQJDQKDWLNURQLNEHUVLIDWSURJUHVLI
lambat dan merupakan penyakit hati kolestatik yang belum diketahui dan sering terjadi pada wanita usia 
pertengahan ,nsidensi 3%&  per  orang per tahun preYalensi  per  orang 
dan semakin meningkat 'iagnosis 3%& berdasarkan kriteria $meriFan $ssoFiation Ior 6tudy oI /iYer 'isease 
didapatkan peningkatan alkali phosphatase antimitoFhondrial antibodies $0$ dan bukti histopatologi -ika 
ditemukan dua dari tiga kriteria tersebut.
Kami melaporkan sebuah kasus yang sangat jarang ditemukan, seorang perempuan, berumur 47 tahun 
dengan keluhan utama penurunan kesadaran dan ikterik. 3ada pemeriksaan ¿sik didapatkan konjungtiYa anemis, 
sklera ikterik, asFites, hepatosplenomegali, palmar eritem dan liYer nail. 3ada pasien tidak didapatkan bukti 
dari imaging obstruksi dengan nilai alkali phospatase meningkat dan nilai AMA positif. Perawatan pasien untuk 
memperlambat perburukan penyakit dan untuk mengatasi gejalagejala misalnya pruritus, osteoporosis dan 
siFFa syndrome. 
Kata kunci: primary biliary Firrhosis, alkali phospatase, antimitoFhondrial antibodies
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INTRODUCTION
 Primary biliary cirrhosis (PBC) is an 
LQÀDPPDWRU\GLVHDVHRUFKURQLF OLYHU LQÀDPPDWLRQ
with slow progressive characteristic and is an unknown 
cholestatic liver disease and commonly happen in 
middle-aged women.1 7KH GH¿QLWLYHPHFKDQLVPRI
PBC is not clearly understood, but is believed to be 
a combination of genetic and environment factors. 
&KURQLF LQÀDPPDWLRQ DQG UHFXUUHQW GDPDJH WR WKH
small biliary duct provoke the proliferation of biliary 
GXFWFHOODQG¿EURVLVFDXVHGE\P\R¿EUREODVWLQWKH
liver mesenchyme. Fibroproliferative biliary duct cells 
is commonly spread to the liver parenchyma, associated 
portal area, leading to biliary cirrhosis. Pathogenesis 
RI¿EURJHQLFUHVSRQVHLQWKHELOLDU\GXFWGDPDJHKDV
been studied with new concept “Hedgehog pathway” in 
the liver, which is a cell differentiation regulator. The 
Hedgehog pathway may help the growth of epithelial 
and stromal cells; disorder in this system may modulate 
the mechanism of biliary duct disturbance.2 
The incidence of PBC is 0.03-5.8 per 100,000 
people per year, prevalence of 1.91-40.2 per 100,000 
people and continues to increase. The diagnosis of 
PBC based on American Association for Study of 
Liver Disease criteria requires the presence of two 
out of three criteria as follows: increase of alkaline 
phosphatase, positive antimitochondrial antibodies 
(AMA), and histopathology evidence .1 The incidence 
of PBC is very rare, which interest the author to report 
this case with the expectation to diagnose this condition 
earlier, accurate, and give appropriate management 
which may increase the patient’s life expectancy.
CASE ILLUSTRATION
A 47-year-old women with the chief complaint 
of decreased consciousness since 5 hours before 
hospital admission which was described as gradual. 
,QLWLDOO\SDWLHQWVOHSWPRUHDQGODWHUEHFDPHGLI¿FXOW
to be awakened. There were no complaints of terrible 
headache, projectile vomiting, slurred speech, or limb 
weakness. The complaint was accompanied with an 
episode of coffee-ground vomiting since 5 hours prior 
to the admission. The patient had no history of black 
stools. The aforementioned symptoms concurred with 
jaundice in both eyes and skin since 1 month before 
the admission. She also reported itching throughout 
her body that had been felt since 2 weeks prior to 
hospitalisation. The patient also lost 10 kg of her weight 
within two months period.
There was no history of fever, dark-coloured urine, 
or clay-coloured stools. No past history of herbal 
medication was reported. None of her relatives had a 
history of jaundice or liver disease. Similar symptoms 
were experienced by the patient 9 years ago that was 
said related to contraceptive pills that she had used 
for 4 years prior to that period. Recently, she resumed 
using contraceptive pills for the last 4 months.
She was treated in Hasan Sadikin Hospital for the 
same symptoms for 1 month and was discharged home 
two days ago. The patient was previously examined for 
the presence of hepatitis marker with a non-reactive 
result. On physical examination, the patient looked 
severely ill and was somnolent. Her blood pressure 
was 120/70 mmHg; pulse 88x/minute, regular, equal 
RQERWK DUPV DQG DGHTXDWH¿OOLQJ UHVSLUDWRU\ UDWH
20x/minute; body temperature 36.8 degree Celsius. 
Upon examination the conjunctiva looked anaemic and 
the sclera was icteric. Neck and chest examinations 
revealed no spider naevi. The abdomen was rounded, 
soft, and showed no venous enlargement; the liver 
was palpated 3 cm below the costal margin and 3 cm 
below the xiphoid process, soft, and had obtuse angle; 
and percussion on Traube’s space was dull. Limb 
examination showed palmar erythema and liver nails.
Laboratory tests revealed hemoglobin 6.4 gr/
dL; haematocrit 18.0%; leukocytes 22.910 103/uL; 
thrombocytes 36.000 thousand/uL; mean corpuscular 
volume (MCV) 102.3 fL; mean corpuscular hemoglobin 
(MCH) 36.4 pg; mean corpuscular hemoglobin 
concentration (MCHC) 35.6 %, basophil 0 %, 
eosinophil 0 %, band neutrophil 3 %, segmented 
neutrophil 73 %, lymphocyte 16 %, monocyte 6 %, 
metamyelocyte 1 %, myelocyte 1 %, random blood 
glucose 93 mg/dL, ureum 48 mg/dL, creatinine 
1.02 mg/dL, sodium 135 mEq/L, potassium 4.2 
mEq/L, aspartate aminotransferase (AST) 155 U/L, 
alanine aminotransferase (ALT) 201 U/L, gamma 
glutamyl transferase (gamma GT) 676 U/L, alkaline 
phosphatase 498 U/L, prothrombin time (PT) 12.90 
second, activated partial thromboplastin time (APTT) 
43.20 second, international normalized ratio (INR) 
1.20, serum protein 4 gr/dL, serum albumin 1.5 gr/
dL reactive antinuclear antibody (ANA), positive for 
antimitochondrial antibody (AMA), total cholesterol 
493 mg/dL, high density lipoprotein (HDL) 9 mg/
dL, low density lipoprotein (LDL) 514 mg/dL, 
triglycerides 212 mg/dL, non-reactive for HBsAg, 
non-reactive for anti-HCV, positive 3 for direct 
Coombs test, negative for indirect Coombs test, 
dark yellow urine, urine was turbid, mass density 
Volume 19, Number 3, December 2018 197
Primary Biliary Cirrhosis
1.015, pH 7.5, negative nitrites, positive 1 for urine 
protein, negative urine glucose, negative ketone in 
urine, normal urobilinogen, positive 3 for bilirubin 
in urine, negative for leukocyte esterase, positive 3 
for blood in urine, abundant erythrocytes, leukocyte 
2, epithelial cells 4; negative for bacteria, crystals, 
and cylinders. She underwent abdominal ultrasound 
that showed enlarged liver, moderately increased 
liver echogenicity, homogenous, no mass, portal and 
hepatic veins were not widened; gallbladder collapsed 
and widened; no intraluminal sludge was observed; 
QR VRQRJUDSKLF0XUSK\ VLJQZDV LGHQWL¿HG VSOHHQ
was enlarged; parailiac and paraaortic lymph nodes 
were not enlarged; minimal ascites was observed. The 
impression from ultrasound was hepatosplenomegaly 
with thickening of the gallbladder possibly due to 
LQÀDPPDWLRQK\SRDOEXPLQHPLDPLQLPDODVFLWHV
The patient was diagnosed with decreased 
consciousness due to hepatic encephalopathy, 
cholestatic jaundice due to primary biliary cirrhosis 
with upper gastrointestinal bleeding due to ruptured 
esophageal varices with differential diagnoses of portal 
hypertension gastropathy, autoimmune haemolytic 
anaemia, thrombocytopenia due to chronic liver 
disease. The patient was treated with bed rest, 3 
OLWUHVSHUPLQXWHRIR[\JHQZKHQVKHZDVGLI¿FXOWWR
breath, NaCl 0.9% infusion 1500 cc/24 hours, dark-
coloured production from NGT (nothing by mouth 
temporarily), albumin 25% transfusion over 6 hours, 
thrombocyte transfusion with a target of > 50.000, 
:5&WUDQVIXVLRQLI+ERUVLJQVRIK\SR[LDZHUH
present; ursodeoxycholic acid (UDCA) 2 x 500 mg, 
lactulose 1 x 15 cc to be taken orally; liver biopsy, vital 
signs, and intake-output monitoring.
DISCUSSION
Primary biliary cirrhosis (PBC) is a chronic 
LQÀDPPDWLRQ VORZ SURJUHVVLYH OLYHU GLVHDVH DQG
is also a cholestatic liver disease with an unknown 
cause that often affects middle-aged women.1 The 
precise mechanism of PBC has not been elucidated 
but was believed to be a combination of genetic and 
environmental factors. The damage of biliary duct 
epithelial cells mediated by the immune system was 
deemed as a trigger in the pathogenesis. The targets 
for antimithochondrial antibodies (AMA) are 3 M2 
components of mithocondrial antigen: PDC-E2, 
2-oxoglutarate dehydrogenase complex (OGDC) and 
branched chain 2-oxo-acid dehydrogenase complex 
(BCOADC). Of these three components, the most 
LGHQWL¿DEOHRQHE\7DQG%FHOOV LV WKH LQQHU OLSR\O
domain of PDC-E2. It is unknown, however, if PDC-E2 
that is localised on mithochondrial membrane of the 
selective biliary epithelial cells and salivary duct cells 
is also a target of autoimmune destruction. The cell 
death presumably increases the exposure of PDC-E2 to 
immune system which resumes as autoimmune attacks. 
Apoptosis or the death of cholangiocytes, unlike any 
other cell death, is a potential source of immunogenic 
3'&(LQSDWLHQWVZLWK3%&&KURQLFLQÀDPPDWLRQ
and recurrent injury of the small biliary duct triggers 
dĂďůĞϭ͘>ĂďŽƌĂƚŽƌǇĞǆĂŵŝŶĂƟŽŶ
Blood examination Urine
Hemoglobin (gr/dL) 6.4 AST(U/L) 155 Colour Yellow 
Haematocrit (%) 18.0 ALT(U/L) 201 Turbidity Hazy 
Erythrocyte (million/uL) 1.76 Gamma GT(U/L) 676 Mass density 1.015
Leukocyte (103/uL) 22.910 Alkaline 
phosphatase(U/L)
498 pH 7.5
Thrombocyte (thousand/uL) 36.000 Total bilirubin (mg/dL) 39.766 Nitrite Negative 
0&9 (fL) 102.3 Direct bilirubin (mg/dL) 28.677 Protein +1
MCH (pg) 36.4 Total protein (gr/dL) 4.0 Glucose Negative
MCHC (%) 35.6 Albumin(gr/dL) 1.5 Ketone Negative
Diff. count (%) 0/0/3/73/16/6/1/1/1 PT (second) 12.90 Urobilinogen Normal
Glucose random (mg/dL) 93 APTT (second) 43.20 Bilirubin +3
Sodium (mEq/L) 135 INR 1.20 LE Negative
Potassium (mEq/L) 4.2 HbsAg Non-reactive Blood +3
Urea (mg/dL) 48 $QWL+&9 Non-reactive Erythrocyte 2
Creatinine (mg/dL) 1.02 AMA Reactive Leukocyte 4
ANA test Reactive HDL(mg/dL) 9
Total cholesterol (mg/dL) 493 Triglyseride 212
LDL (mg/dL) 514 Coomb test Direct +3
0&9PHDQFRUSXVFXODUYROXPH0&+PHDQFRUSXVFXODUKHPRJORELQ0&+&PHDQFRUSXVFXODUKHPRJORELQFRQFHQWUDWLRQ'LIIFRXQWGLIIHUHQWLDOEORRGFRXQW
ANA test: antinuclear antibody test; LDL: low-density lipoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; Gamma GT: gamma-glutamyl 
transferase; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; HbsAg: hepatitis B surface antigen; Anti 
+&9DQWLKHSDWLWLV&YLUXV$0$DQWLPLWRFKRQGULDODQWLERG\+'/KLJKGHQVLW\OLSRSURWHLQ/(/XSXVHU\WKHPDWRVXV
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WKHSUROLIHUDWLRQRIELOLDU\GXFWFHOOVDQG¿EURVLVFDXVHG
E\P\R¿EUREODVWFHOOVZLWKLQWKHKHSDWLFPHVHQFK\PH
Fibroproliferative biliary duct cells often expands to 
liver parenchyme and associated portal area towards 
a process of biliary cirrhosis. The pathogenesis of 
¿EURJHQLF UHVSRQVH LQ ELOLDU\ GXFW LQMXU\ KDV EHHQ
studied using a new concept of “Hedgehog pathway” 
in the liver that regulates the cell differentiation system. 
The Hedgehog pathway shows its ability to promote 
the growth of epithelial and stromal cells and the 
interruption of such system can modulate the disruptive 
mechanism in biliary duct.2
The patient came with problems of decreased 
consciousness and coffee-ground vomiting since 5 
hours prior to hospital admission, as well as yellowing 
of eyes and body since 1 month prior to admission. 
The determination of diagnosis and aetiology needs 
a thorough anamnesis to identify the cause of this 
patient’s loss of consciousness. From the history taking, 
it was found that the patient suffered from jaundice of 
eyes without an episode of fever nor history of certain 
drugs and alcohol consumption, tuberculosis treatment, 
familial history of jaundice, and upper abdominal 
discomfort. Physical examination suggested signs of 
hepatic failure and portal hypertension which were 
hepatosplenomegaly, ascites, palmar erythema, and 
liver nails. Findings from history taking and physical 
examination hinted a diagnosis of liver cirrhosis that 
was supported by following additional examinations.
Additional tests revealed thrombocytopenia, ratio of 
albumin-globulin with APRI score > 2 which explained 
the presence of liver cirrhosis in this patient. Decreased 
consciousness is a part of cirrhosis complication, which 
is grade III hepatic encephalopathy. In this patient, 
there was no evidence of infection nor acute liver 
failure. In addition, coffee-ground vomiting in this 
patient was a part of liver cirrhosis complication, i.e. 
upper gastrointestinal bleeding (variceal bleeding). 
From this data, it was concluded that the diagnosis 
was a decreased consciousness caused by hepatic 
encephalopathy.1,2,3,4,5
The diagnostic approach was based on the icterus 
that the patient experienced since 1 month prior 
(Figure 1).6 This patient had yellowing of eyes and 
body since 1 month ago, accompanied by body 
Figure 1. Diagnostic approach in jaundice6
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weakness, generalised itching throughout the body 
and coffee-ground stools. There was neither history 
of fever, colour change of urine looking like dark tea, 
clay-coloured stool, nor upper abdominal pain. There 
was also no history of drugs consumption, tuberculosis 
treatment, or drinking alcohols. Laboratory data with 
5YDOXH  VXSSRUWHG WKH GLDJQRVLV RI FKROHVWDWLF
jaundice.
From the above algorithm, jaundice can be caused 
by pre-hepatic, hepatic, and post-hepatic causes. 
Table 2. Differential diagnosis in jaundice7
Pre Hepatic Haemolytic 
Antibiotic medications
Thalassemia 
Hepatic 9LUDOKHSDWLF
Alcoholic hepatic
Primary biliary cirrhosis
Primary sclerosing cholangitis
,Q¿OWUDWLYHGLVHDVH7%O\PSKRPDDP\ORLGRVLV
Infection (malaria, leptospirosis)
Gilbert’s syndrome
Crigler-Najjar syndrome
Post hepatic Cholestatic extrahepatic
Gallstones
Biliary duct tumour
Pancreatic carcinoma
&DUFLQRPDRI9DWHUDPSXOOD
Diagnostic approach in the suspect of primary 
biliary cirrhosis (Figure 2).1 Patient with two-fold 
increase of alkaline phosphatase  serum and no 
evidence of obstruction in biliary duct from USG 
examination.
(antimithochondrial antibodies); (3) histopathological 
evidence of non-suppurative destructive cholangitis 
and injury of interlobular biliary duct on liver biopsy. 
The recommended diagnosis of primary biliary 
cirrhosis develops if two of these three criteria are 
found.1,2
%DVHGRQWKH¿QGLQJVIURPKLVWRU\WDNLQJSK\VLFDO
examination, laboratory and further tests, it was 
concluded that the cause of jaundice in this patient 
was primary biliary cirrhosis. It was supported by the 
results from ultrasound that showed enlarged liver, 
moderate increase in liver echogenicity, homogenous, 
without mass, no enlargement of vena porta and 
vena hepatica, widened of collapsed gallbladder, no 
intraluminal sludge, no sonographic Murphy sign, 
enlarged spleen, no enlargement of parailiac and 
paraaortic lymph nodes, and minimal ascites. The 
impression from ultrasound was hepatosplenomegaly 
with thickening of gallbladder possibly due to 
LQÀDPPDWLRQK\SRDOEXPLQHPLDDQGPLQLPDODVFLWHV
Loss of consciousness in this patient was caused by 
hepatic encephalopathy as seen in patients with primary 
biliary cirrhosis and portal hypertension. From the case 
report, the patient had PBC with the feature of low 
haemoglobin with patterns of autoimmune haemolytic 
anaemia. This patient had low haemoglobin level and 
SRVLWLYHGLUHFW&RRPEVWHVWWKDWPDWFKHGWKH¿QGLQJV
from autoimmune haemolytic anaemia. 
It was concluded that the patient was diagnosed 
with decreased consciousness due to hepatic 
encephalopathy, cholestatic jaundice due to primary 
biliary cirrhosis with upper gastrointestinal bleeding 
due to ruptured oesophageal varices with differential 
diagnosis of portal hypertension gastropathy, Evans 
syndrome due to primary biliary cirrhosis based on 
gradual loss of consciousness since 5 hours prior to 
hospital admission and jaundice since 1 month before 
that. Physical examination revealed signs of chronic 
liver disease. On additional tests, increased alkaline 
SKRVSKDWDVHDQGSRVLWLYH$0$UHVXOWVZHUHLGHQWL¿HG
while ultrasound showed no obstruction. Liver biopsy 
has not been performed in this patient.
The diagnostic approach for primary biliary 
cirrhosis was based on the criteria from American 
Association for Study of Liver Disease (AASLD): 
(1) biochemical evidence of cholestasis shown by 
increased alkaline phosphatase activity (the magnitude 
of increased activity correlates with the severity of 
GXFWRSHQLDDQGLQÀDPPDWLRQWKHUHZDVQRFRQVHQVXV
on the degree of escalation in primary biliary cirrhosis), 
for at least 6 months; (2) the presence of AMA 
Figure 2. Diagnostic approach in the suspect of Primary Biliary 
Cirrhosis1
 
Increased alkali phosfatase
No history of alcohol consumption or drug use
Evidence of the absence of obstruction
ANA, AMA, ASMA
Liver biopsy, particularly if AST > 5 fold of normal limit 
or AMA?





        
Ursodeoxycholic acid/UDCA (13-15 mg/kg/day)
WƌƵƌŝƚƵƐ
Antihistamin 
Cholestyramine 
Rifampin 
Naloxone/naltrexone 
Sertraline
^ŝĐĐĂ
Artificial tears 
Cevimeline 
Ophtalmic Cyclosporin 
ŽŶĞĚŝƐĞĂƐĞ
Calsium +/- 
vitamine D  
Alendronate 
Figure 3. Management symptoms of primary biliary cirrhosis1
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The aim of treatment in primary biliary cirrhosis 
is to diminish the disease progression and to alleviate 
accompanying symptoms (e.g. pruritus, osteoporosis, 
and sicca syndrome). Below is the treatment algorithm 
based on the recommendation from American 
Association for Study of Liver Disease: 1,3,8,9,10
UDCA treatment using the recommended dose 
RI PJNJGD\ LV FRQVLGHUHG DV WKH ¿UVW OLQH
treatment for PBC. UDCA is a natural hydrophilic 
bile acid that has a function related to hydrophilic bile 
DFLGSRROZLWKDGLUHFWFKROHUHWLFDQWLLQÀDPPDWLRQ
and anti-apoptosis of the liver epithelial cells effects. 
Various adjunct treatment can be given to patients 
with suboptimal UDCA response, including steroids, 
azathioprine, mycophenolate mofetil, methotrexate, 
FROFKLFLQHV\OPDULQHDQGEH]D¿EUDWH&RUWLFRVWHURLGV
is known for its effect in improving serum liver 
function and liver histological appearance, but it may 
deteriorate the bone mineral density. The combination 
of prednisolone (10 mg/day, for 9 months) with UDCA 
(10 mg/kg/day) is better in improving liver histology 
in PBC during early phase than UDCA alone.1,3
The patient was treated with UDCA but only 
received it when her condition was affected by hepatic 
encephalopathy. This treatment has not shown a 
VLJQL¿FDQWLPSURYHPHQW
Liver transplantation may increase the survival of 
patients with PBC and is effective for decompensated 
cirrhosis or liver failure. Approximately 20% of 
SDWLHQWV KDYH UHFXUUHQW3%&ZLWKLQ¿YH\HDUV DIWHU
transplantation. Pruritus is often refractory to medical 
WUHDWPHQW DQGPLJKW LQÀXHQFH WKH SDWLHQW¶V TXDOLW\
RI OLIH7KH ¿UVW OLQH RIPLOGPRGHUDWH SUXULWXV LV
antihistamine, which should be taken cautiously in 
patient with cirrhosis and signs of encephalopathy 
because antihistamine may suppress brain function 
even further.1,3 Detection of patients with PBC should 
be performed during early signs of jaundice so that 
proper treatment can be given since the presence of 
its early symptoms. 
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